Eli Lilly (LLY) Short-term Investments (2009 - 2025)

Eli Lilly has reported Short-term Investments for 17 years, with the latest figure at $121.6 million in Q3 2025.

• For the quarter ending Q3 2025, Short-term Investments fell 18.61% year-over-year to $121.6 million; the trailing twelve-month figure through Sep 2025 stood at $121.6 million (down 18.61% YoY), and the FY2024 full-year result was $154.8 million, up 41.89% from the prior year.
• Short-term Investments for Q3 2025 stood at $121.6 million, down from $170.1 million in the prior quarter.
• The five-year high for Short-term Investments was $170.1 million in Q2 2025, with the low at $37.1 million in Q3 2021.
• Historically, Short-term Investments has averaged $115.3 million across 5 years, with a median of $123.4 million in 2023.
• The largest YoY upside for Short-term Investments was 272.31% in 2021 against a maximum downside of 37.5% in 2021.
• Eli Lilly's Short-term Investments stood at $90.1 million in 2021, then surged by 60.71% to $144.8 million in 2022, then decreased by 24.65% to $109.1 million in 2023, then surged by 41.89% to $154.8 million in 2024, then decreased by 21.45% to $121.6 million in 2025.
• The last three Short-term Investments figures came in at $121.6 million (Q3 2025), $170.1 million (Q2 2025), and $127.4 million (Q1 2025), per Business Quant data.